Abstract:Background: Despite the introduction of targeted therapies, most patients with myeloid malignancies will not be cured and progress. Genomics is useful to elucidate the mutational landscape but remains limited in the prediction of therapeutic outcome and identification of targets for resistance. Dysregulation of phosphorylation-based signaling pathways is a hallmark of cancer, and therefore, kinase-inhibitors are playing an increasingly important role as targeted treatments. Untargeted phosphoproteomics analysis pipelines have been published but show limitations in inferring kinase-activities and identifying potential biomarkers of response and resistance. Methods: We developed a phosphoproteomics workflow based on titanium dioxide phosphopeptide enrichment with subsequent analysis by liquid chromatography tandem mass spectrometry (LC-MS). We applied a novel Kinase-Activity Enrichment Analysis (KAEA) pipeline on differential phosphoproteomics profiles, which is based on the recently published SetRank enrichment algorithm with reduced false positive rates. Kinase activities were inferred by this algorithm using an extensive reference database comprising five experimentally validated kinase-substrate meta-databases complemented with the NetworKIN in-silico prediction tool. For the proof of concept, we used human myeloid cell lines (K562, NB4, THP1, OCI-AML3, MOLM13 and MV4-11) with known oncogenic drivers and exposed them to clinically established kinase-inhibitors. Results: Biologically meaningful over- and under-active kinases were identified by KAEA in the unperturbed human myeloid cell lines (K562, NB4, THP1, OCI-AML3 and MOLM13). To increase the inhibition signal of the driving oncogenic kinases, we exposed the K562 (BCR-ABL1) and MOLM13/MV4-11 (FLT3-ITD) cell lines to either Nilotinib or Midostaurin kinase inhibitors, respectively. We observed correct detection of expected direct (ABL, KIT, SRC) and indirect (MAPK) targets of Nilotinib in K562 as well as indirect (PRKC, MAPK, AKT, RPS6K) targets of Midostaurin in MOLM13/MV4-11, respectively. Moreover, our pipeline was able to characterize unexplored kinase-activities within the corresponding signaling networks. Conclusions: We developed and validated a novel KAEA pipeline for the analysis of differential phosphoproteomics MS profiling data. We provide translational researchers with an improved instrument to characterize the biological behavior of kinases in response or resistance to targeted treatment. Further investigations are warranted to determine the utility of KAEA to characterize mechanisms of disease progression and treatment failure using primary patient samples.

Multiplexed Quantitative MALDI MS Approach for Assessing Activity and Inhibition of Protein Kinases Based on Postenrichment Dephosphorylation of Phosphopeptides by Metal-Organic Framework-Templated Porous CeO2.

Quantitative Mass Spectrometry Combined with Separation and Enrichment of Phosphopeptides by Titania Coated Magnetic Mesoporous Silica Microspheres for Screening of Protein Kinase Inhibitors.

Inhibitor Screening of Protein Kinases Using MALDI-TOF MS Combined with Separation and Enrichment of Phosphopeptides by TiO2 Nanoparticle Deposited Capillary Column

A Targeted Quantitative Proteomics Strategy for Global Kinome Profiling of Cancer Cells and Tissues

Multiplex Imaging and Cellular Target Identification of Kinase Inhibitors via an Affinity-Based Proteome Profiling Approach

Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS

Proteomic Sensors for Quantitative, Multiplexed and Spatial Monitoring of Kinase Signaling

Multiplexed tyrosine kinase activity detection in cancer cells using a hydrogel immobilized substrate

Multiplex analysis of Src family kinase signaling by microbead suspension arrays

Characterization of the Novel Broad-Spectrum Kinase Inhibitor CTx-0294885 As an Affinity Reagent for Mass Spectrometry-Based Kinome Profiling.

Improvement Of The Quantification Accuracy And Throughput For Phosphoproteome Analysis By A Pseudo Triplex Stable Isotope Dimethyl Labeling Approach

High-Throughput Screening of Kinase Inhibitors by Multiplex Capillary Electrophoresis with Uv Absorption Detection

Kinase inhibitor pulldown assay (KiP) for clinical proteomics

Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA)

Development of a high-throughput kinase activity platform using nanoLC-MS/MS with DIA approach for studying the anti-cancer mechanism of Taxol in ovarian cancer

Quantitative proteomic mass spectrometry of protein kinases to determine dynamic heterogeneity of the human kinome

Integrating Phosphoproteomics into Kinase-Targeted Cancer Therapies in Precision Medicine.

An Automated High-throughput Affinity Capture-Mass Spectrometry Platform with Data-Independent Acquisition

A Road Map to Evaluate the Proteome-Wide Selectivity of Covalent Kinase Inhibitors.

diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction Profiling

Optimized chemical proteomics assay for kinase inhibitor profiling.